China's Gaush Meditech H1 revenue falls on distribution product decline

Gaush Meditech

28/08/2026 11:08

Overview
China ophthalmic equipment maker's H1 revenue fell 8.9% yr/yr to RMB595.1 mln
Net profit for H1 dropped 57.9% yr/yr to RMB15.1 mln
Company cites adverse market factors and policy changes for revenue decline

Outlook
Gaush expects several self-developed products to enter mass production and launch in H2 2026, supporting sustained revenue growth

Result Drivers
DISTRIBUTION PRODUCT DECLINE – Revenue fell 8.9%, as policy-driven demand shifts and a terminated femtosecond-laser agency agreement cut distribution-product sales 19.4%
INTRAOCULAR LENS GROWTH – Proprietary intraocular-lens revenue rose 11.0%, supported by national procurement expanding customer coverage and overseas growth
OVERSEAS EXPANSION COSTS – Administrative expenses rose 4.9% on international-business hiring and severance costs from relocating China functions

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 595.1 mln
 

Analyst Coverage
The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 5 three months ago

Reuters Recommended Reads
Aug 28 - China's Chaoju Eye Care H1 net profit falls on lower insurance pricing
Aug 25 - Hong Kong's SV Vision H1 revenue dips
Aug 25 - China's Weigao H1 profit falls 23% as price drops, competition hit margins

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)